title: Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease.
authors.affiliation: Division of Gastroenterology, Department of Medicine, University of Calgary, Calgary, AB, Canada. rpanacci@ucalgary.ca
authors.forename: R
authors.initials: R
authors.lastname: Panaccione
authors.forename: J-F
authors.initials: JF
authors.lastname: Colombel
authors.forename: W J
authors.initials: WJ
authors.lastname: Sandborn
authors.forename: P
authors.initials: P
authors.lastname: Rutgeerts
authors.forename: G R
authors.initials: GR
authors.lastname: D'Haens
authors.forename: A M
authors.initials: AM
authors.lastname: Robinson
authors.forename: J
authors.initials: J
authors.lastname: Chao
authors.forename: P M
authors.initials: PM
authors.lastname: Mulani
authors.forename: P F
authors.initials: PF
authors.lastname: Pollack
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D003424:Crohn Disease / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068879:Adalimumab